



BIOST/STAT 578 A  
Statistical Methods in Infectious Diseases  
Lecture 8  
January 29, 2009

Stochastic epidemic models: Pandemic influenza I

# THE INFLUENZA VIRUS



# Influenza Transmission

- Droplet




– Droplet nuclei (air borne)

- Fomites (things)



# 20<sup>th</sup> Century Flu Strains & Pandemics



1918: "Spanish Flu"


1957: "Asian Flu"

1968: "Hong Kong Flu"

40-50 million  
deaths,  
~ 2.0%

1 million  
deaths,  
~ 0.02%

1 million deaths



# Playing Roulette



Yearly chance of pandemic is about  $1/33.3$  or about 3%

# On Influenza Epidemics


**"God does not play dice with the universe" Albert Einstein**

**"Except in the case of influenza..." Me**

**"If you've seen one influenza epidemic, you've seen one influenza epidemic!"**

# Areas reporting confirmed occurrence of H5N1 avian influenza in poultry and wild birds since 2003

Status as of 12 December 2008  
Latest available update



© WHO 2008. All rights reserved


The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

**Data Source: World Organisation for Animal Health (OIE) and national governments**  
Map Production: Public Health Information and Geographic Information Systems (GIS), World Health Organization

# Cumulative 397 reported cases, 249 deaths, 63% case fatality ratio in 15 countries 31 documented family clusters, human-to-human transmission has occurred.

Status as of 16 December 2008  
Latest available update

Areas with confirmed human cases of H5N1 avian influenza since 2003 \*



# ***CHICKEN RUN*** ***IV***

***Bird Flu!***



# Current WHO phase of pandemic alert

- [WHO global influenza preparedness plan](#)

<b>Inter-pandemic phase</b> New virus in animals, no human cases	Low risk of human cases	1
	Higher risk of human cases	2
<b>Pandemic alert</b> New virus causes human cases	No or very limited human-to-human transmission	3
	Evidence of increased human-to-human transmission	4
	Evidence of significant human-to-human transmission	5
<b>Pandemic</b>	Efficient and sustained human-to-human transmission	6

# How Bad Could it Get Today?

- Global pandemic, first wave about 6 - 9 months, 2 billion cases
  - 1918 scenario: 10 - 62 million deaths
  - Contrast
    - 20 million AIDS deaths over 25 years
    - 811 SARS deaths over 8 months, \$30 billion world economy

# Containment of pandemic influenza at the source

- It is optimal to stop a potential pandemic influenza strain at the source
  - An effective method would be with pre-pandemic vaccination or rapid vaccination, even with a poorly matched vaccine (WHO) ~ 50 million doses (GSK)
  - Targeted antiviral prophylaxis with mobile stockpile (WHO) ~ 5 million courses oseltamivir (Roche)
  - Quarantine, social distancing, school closing, travel restrictions
  - Longini, et al. *Science* 309 (2005).
  - Longini and Halloran. *Science* 310 (2005).
  - Ferguson, et al. *Nature* 437 (2005)

Draft  
**WHO pandemic influenza  
draft protocol for rapid  
response  
and containment**  
**Updated draft 30 May 2006**



# Pandemic Influenza in the US or Other Countries Once the Pandemic Spread is Global

- Firstly, since early vaccination is key in slowing the spread, countries should be prepared with vaccine stockpiles
- Hard to contain as it comes in
- Once widespread, slow transmission until well-matched/pandemic vaccine is available
  - Rapid vaccination with a possibly poorly match vaccine/pre-pandemic vaccine
  - Targeted antiviral prophylaxis
  - Quarantine, social distancing, school closing, travel restrictions
- Germann, T.C., Kadau, K., Longini I.M. and Macken C.A.: *PNAS* 103 (2006)
- Ferguson, N.M., *et al.*: *Nature* 442 (2006)
- Halloran, M.E. and Longini, I.M.: *Science* 311 (2006)
- Halloran, M.E., Ferguson, N.M., Eubank, S., Longini, I.M., *et al.* : *PNAS* 105 (2008)

# US Plan




# HHS Pandemic Influenza Plan

## Strategic Plan (Part 1)

- Outlines planning assumptions and doctrine for the HHS pandemic influenza response

## Public Health Guidance for State and Local Partners (Part 2)

- 11 Supplements provide detailed guidance



[www.pandemicflu.gov](http://www.pandemicflu.gov)

# Measures of Vaccine Efficacy\*

- $\{VE(t)_S, VE(t)_P, VE(t)_I\}$
- $VE_S$  Vaccine Effect on Susceptibility
  - Classical III vaccine trials
    - Many times observe
$$VE_{SP} = 1 - (1 - VE_S)(1 - VE_P)$$
  - Phase I and II vaccine trials
    - Correlates of immunity
  - Virus challenge studies in humans or animals

\*Halloran, Longini, Struchiner: Design and interpretation of vaccine field studies. *Epidemiol Rev* **21**, 73- 88 (1999).

# Measures of Vaccine Efficacy

- $VE_P$  Vaccine Effect on Clinical Disease
  - Possible phase III vaccine trials if infection in both symptomatic and asymptomatics is included
  - Usually only  $VE_{SP}$  is available
  - Virus challenge studies in humans or animals

# Measures of Vaccine Efficacy

- $VE$ , Vaccine Effect on Infectiousness
  - Vaccine trials in households or other small transmission groups
  - Teased out of indirect effects (community randomized vaccine trials, modeling)
  - Virus challenge studies in humans or animals

# Measures of Vaccine Efficacy

- $VE_C$  Combined Efficacy
  - Combination of  $VE_S$ ,  $VE_P$ ,  $VE_I$ , relative infectiousness of asymptomatics ( $m$ ) and pathogenicity ( $k$ ).

$$VE_C = 1 - \frac{R_1}{R_0} = 1 - \frac{\theta\phi((1-\psi k)m + \psi k)}{(1-k)m + k},$$


where,  $\theta = 1 - VE_S$ ,  $\phi = 1 - VE_I$ , and  $\psi = 1 - VE_P$

# Old Challenge Studies in Humans

- Vaccine Efficacy Estimates Based on Challenge Studies in Seronegative Adults
- Homologous and Heterologous Challenge
- We can estimate VE parameters without phase III trial, but how applicable?




# Absolute Efficacy of Live Influenza Vaccine



Source: Basta, Halloran, Longini: *Amer J Epidemiol* (2008)



# Absolute Efficacy of Inactivated Influenza Vaccine



Source: Basta, Halloran, Longini: *Amer J Epidemiol* (2008)

# A Note On Seroprotection


- An HI titer of at least 1:32 to 1:40 is considered to result in protection for 50% of the population ( Plotkin, et al. *Vaccines*, 2008)
- A CHMP requirement for immunogenicity is seroprotection > 70%

Infection rates by pre-season antibody titer:  
 influenza A(H3N2) epidemic season 1977-  
 1978 and 1980-1981 combined,  
 Tecumseh, Michigan \*

Pre-season antibody titer (1:X)	No. observed	Fraction Infected	Antibody Efficacy
< 8	836	0.23	-
8	267	0.14	0.39
16	153	0.06	0.74
32	137	0.09	0.61
64	87	0.05	0.78
≥ 128	26	0.00	1.00
Total	1,506	0.17	


\* Source: Longini, *et al. AJE*, **128** (1988)

# Cell Mediated Immunity Gamma Interferon\*



\*Source: Forrest, et al., Clin. Vaccine Immunol. (April, 2008 on line)

# Cell Mediated Immunity Vaccine and Naturally Induced\*




\*Source: Forrest, et al., Clin. Vaccine Immunol. (April, 2008 on line)

# GSK Pandemic Influenza Vaccine\*

- Split, inactivated, adjuvanted with AS03
  - Requires two doses (3 weeks apart) in humans
  - Antigen-sparing properties (3.8  $\mu$ g/dose)
  - Broad seroprotective heterologous response
  - Safe

\*Leroux-Roels, et al. Lancet 370, 580-589 (2007)

# Antigen Sparing for Protection After 2<sup>nd</sup> Dose\*




\*Source: Roland Sanger, GSK



What we conclude at this point  
about VE parameters for  
heterologous virus

Combined vaccine efficacy for weeks 1, 2 and 4



# VE Parameters

- Based on clinical studies in humans
  - Overall:  $VE_{SP} = 60 - 70\%$ 
    - Get  $\leq \frac{1}{2}$  way there after 1<sup>st</sup> dose
- Based on ferret challenge studies
  - $VE_1 = 0.70$
  - e.g., viral shedding in the URT: (throat or nasal swab) 26.1% of treatment group, 91.7% of controls
    - $VE_1 = 1 - (26.1/91.7) = 0.72$


# Modeled Vaccine Efficacy

---

t	0	14	21	28
$VE_S(t)$	0	0.05	0.05	0.10
$VE_P(t)$	0	0.30	0.30	0.60
$VE_{SP}(t)$	0	0.34	0.34	0.64
$VE_I(t)$	0	0.35	0.35	0.70
$VE_C(t)$	0	0.46	0.46	0.79

---

Vaccine efficacies as functions of time



# Antiviral efficacies used in the model: Oseltamivir or zanamivir\*

- Antiviral efficacy of reducing susceptibility to infection:  **$AVE_s = 0.30$**
- Antiviral efficacy of reducing illness given infection:  **$AVE_p = 0.60$**
- Antiviral efficacy of reducing illness with infection:  **$AVE_{SD} = 0.72$**
- Antiviral efficacy of reducing infectiousness to others:  **$AVE_i = 0.62$**
- Resistance could become a problem
  - Transmissibility of resistant strains
  - e.g., Norway, 66% A(H1N1) strains resistant to oseltamivir, February, 2008; US, 98% resistant to oseltamivir, January, 2009


\*data from Welliver, *et al. JAMA* (2001); Hayden, *et al. JID* (2004); analysis from Yang, Longini, Halloran, *Appl Stat* (2006); Halloran, *et al. Am J Epidemiol* (2007).

# TAP

xx% school



xx% ascertainment



xx% household + HH cluster



xx% workplace

## CONTACTS

- Household
- Household cluster
- Preschool/daycare
- School
- Workplace


xx% preschool



**TAP: Targeted antiviral prophylaxis using neuraminidase inhibitors (oseltamivir/zanamivir)**

# Large-Scale, Individual-based, Stochastic Simulation Models

# Vaccination Strategy Timing



# Pre-pandemic Vaccination Strategies


- Mass pre-vaccination
  - Two doses starting at least four weeks before initial case
- Reactive mass vaccination
  - Begin vaccinating  $x$  days after first case in a geographic region
- Ring vaccination
  - Begin vaccinating  $x$  days after first case in ring, then in a ring after each subsequent case
- Pre-prime, post-boost vaccination
  - One dose at least three weeks before the initial case, begin vaccinating  $x$  days after the first case with mass or ring reactive

# Basic Reproductive Number Pandemic Influenza

For pandemic influenza:  $1 < R_0 \leq 2.4$


- A(H3N2) 1968-69,  $R_0 \approx 1.7$
- A(H1N1) 1918, second wave,  $R_0 \approx 2.0$
- New variant, early spread:  $1 < R_0 \leq 1.6$ 
  - Estimate of  $R_0 = 1.14$  (95% CI, 0.61-2.14) for A(H5N1) in Northern Sumatra, Indonesia
    - Yang, et al. *Emer Inf Dis* **9**, 1348-1353 (2007).

# The influenza attack rate is influenced by age and $R_0$ (no intervention)





The higher  $R_0$ , the earlier and the higher the peak incidence of the pandemic





## Goal of Modeling:

- Contain a reassorted or mutated strain of influenza at the source
- Avian A(H5N1) is the most likely virus
- Source could be in SE Asia




# Rural population of 500,000 in Thailand

Population matched to non-municipal area household-size and age distributions.\*

Avg. household size 3.6.

\*Population and Housing Census 2000 data used where available ([www.nso.go.th](http://www.nso.go.th)); other National Statistical Office reports and tables used as necessary.



## Population Characteristics

- 36 localities each of size ~14,000
- Total area: 75 km X 75 km = 5,625 km<sup>2</sup>
- Population density ~89/km<sup>2</sup>


# Localities Characteristics

- ~ 28 villages, each of size ~ 138 households, ~ 500 people

- Villages are clustered

Within village clusters:

- Household are clustered
- Small & large playgroups
- Elementary, lower-secondary and upper-secondary school mixing groups
- Social groups
- Work groups



# Household composition

## Household Size Distribution (Non-municipal Areas)

<u># Persons</u>	<u>% of Households</u>
1	7.3%
2	15.3%
3	24.1%
4	29.8%
5	17.6%
6	3.0%
7	1.5%
8	0.7%
9	0.3%
10+	0.3%

# Age distribution

## Age Distribution (Non-municipal Areas)

<u>No.</u>	<u>Age (Yrs)</u>	<u>%</u>
1	< 6mos	0.9%
2	6mos - 4 yrs	8.2%
3	5-10	11.0%
4	11-14	5.5%
5	15-17	5.5%
6	18-44	44.4%
7	45-64	18.3%
8	65+	6.3%

# What we incorporate from the Nang Rong District study\*

- 310 villages under study
- Village size average  $\approx$  100 households
- Main mixing groups under study
  - ◆ Households
  - ◆ Villages
  - ◆ Hiring tractors
  - ◆ Temples
  - ◆ Elementary schools
  - ◆ Secondary schools
  - ◆ Workplaces

\*Faust, et al., *Soc Net* (1999)

# Nang Rong District\*

- Close clusters of villages
  - ◆ Temples
    - ☞ 36% of villages
    - ☞ link villages aver 1.48 km apart
  - ◆ Elementary schools
    - ☞ 31% villages
    - ☞ link villages ave 2.11 km apart

\*Faust, et al., *Soc Net* (1999)

# Nang Rong District\*

- Wider clusters of villages
  - ◆ Tractor Hiring
    - ☞ 41% villages involved
    - ☞ link villages ave 5.28 km apart
  - ◆ Labor movement
    - ☞ link villages ave 4.77 km apart
  - ◆ Secondary schools
    - ☞ 5.5% villages
    - ☞ link villages ave 5.26 km apart

\*Faust, et al., *Soc Net* (1999)

# Nang Rong District\*

- Percent of villages with no ties outside of district
  - ◆ Tractor Hiring 74%
  - ◆ Temple Sharing 99%
  - ◆ Elementary schools 95%
  - ◆ Secondary schools 13%
  - ◆ Labor movement 87%

\*Faust, et al., *Soc Net* (1999)

# Children's Playgroups

## Small Playgroups:

- children 6 months - 4 years
- average size: 4

## Larger Playgroups:

- children 6 months – 4 years
- average size: 22

# Schools

## Elementary schools:

- Children 5-10yrs old from village cluster
- 2 schools per community, avg. size 117

## Lower-secondary schools:

- Children 11-14yrs old from various localities randomly assigned to schools based on travel distribution
- 1 school per community, avg. size 95
- 17% of lower-secondary school age children do not attend school\*

\*Population and Housing Census 2000 data used where available ([www.nso.go.th](http://www.nso.go.th)); other National Statistical Office reports and tables used as necessary.

# Schools

## Upper-secondary schools:

- Children 15-17yrs old from various localities, randomly assigned based on travel distribution
- 1 school per community, avg. size 69
- 42% of higher-secondary-age children do not attend school\*

\*Population and Housing Census 2000 data used where available ([www.nso.go.th](http://www.nso.go.th)); other National Statistical Office reports and tables used as necessary.

# Work groups

## Work Groups:

- Consist of adults and children 11-17 who are not attending school.
- 82% of adults are in the labor force\*
- average group size: 25
- group members are randomly assigned and come from various localities, according to travel distribution

\*Population and Housing Census 2000 data used where available ([www.nso.go.th](http://www.nso.go.th)); other National Statistical Office reports and tables used as necessary.

# Social groups

## Social Groups:

- All individuals are members of two social groups.
- average group size: 100
- members are randomly assigned and come from various localities, according to travel distribution

\*Population and Housing Census 2000 data used where available ([www.nso.go.th](http://www.nso.go.th)); other National Statistical Office reports and tables used as necessary.

# Hospital

- One centrally located 40-bed community hospital serving the 36 localities<sup>1</sup>
  - ◆ Age-specific hospitalization rates from '93-'94 Hong Kong physician sentinel data<sup>2</sup> used to select cases for hospitalization
  - ◆ If hospital is full, flu cases selected for hospitalization withdraw to “holding center” instead
    - ☞ One holding center of size 100 in each locality
  - ◆ If both hospital and holding centers are full, flu cases selected for hospitalization withdraw to the home instead
  - ◆ Staff of 125 persons works at the hospital

1. Thailand Health Profile 1999-2000, pp.279-291.  
[http://www.moph.go.th/ops/thealth\\_44/](http://www.moph.go.th/ops/thealth_44/)


2. Fitzner et al, *Hong Kong Med J*, 1999

# Hospitalization probabilities for a flu-like illness\*

<u>Age</u>	<u>Prob</u>
<1	0.0023
2-4	0.0025
5-17	0.0008
18-64	0.0007
<u>65+</u>	<u>0.0015</u>

\*Fitzner et al, *Hong Kong Med J*, 1999

# Distribution of travel distance to work, school and social groups




# Secondary school, work and social group assignment

- Subpopulations are linked by secondary schools, work groups and social groups
- For residents of each subpopulation, Secondary school, work group and social group subpopulation is selected according to distance distribution shown below (using subpopulation 1 as an example)

Zone6						<u>Zone</u>	<u>%</u>
Zone5						1	90
Zone4						2	7
Zone3						3	2
Zone2						4-6	1
Zone1							

# Distribution of travel distance to work, school and social groups\*

For residents of subpopulation 1:



# Population Movement Outside of Area

- Individual migration probability for rural Thailand is on the order of  $1/10,000$  per day\*
- Modeled individual level short term trip probability is on the order of  $1/1,000$

\*Guest, et al. *Asian and Pacific Migration J* (1994)

# Other parameters

- Transmission probability:  $x$  varies
- Household and household cluster contact probabilities doubled when schools or other local groups are closed.
- 100 simulations per scenario
- Results averaged over simulations where at least one additional case occurs

# Basic Reproductive Number: $R_0$

***Average*** number of people that a (one) ***typical*** infected person infects over the course of his or her infectious period in ***completely susceptible*** population.

- $R_0 > 1$  for sustained transmission
- For pandemic influenza:  $1 < R_0 \leq 2.4$ 
  - ◆ A(H3N2) 1968-69,  $R_0 \approx 1.7$
  - ◆ A(H1N1) 1918, second wave,  $R_0 \approx 2.0$
  - ◆ New variant, early spread:  $1 < R_0 \leq 1.6$

# Model calibration

---

	Illness Attack Rate		
		Modeled	
	Asian A(H2N2) 1957-58	Pandemic Strain	HK-Like '68-69
Young Children	35%	32%	34%
Older Children	62%	45%	35%
Adults	24%	29%	33%
Overall	33%	33%	34%

---

# Social Connectivity

# Transmission

- $c$  daily adequate contact probability
  - ◆  $c(n-1)$  average mixing group degree
- $x$  transmission probability given adequate contact
- $y$  relative susceptibility
- $p = cxy$  overall transmission probability

# Infection Probability Each Day

- e.g., susceptible person on antivirals on day  $t$

- $AVE_S = 1 - \mathbb{E}[\text{skull}], AVE_I = 1 - \mathbb{E}[\text{skull}]$

- Sequence of Bernoulli trials

- Escape probability

$$Q(t) = (1 - \mathbb{E}[p_1])^{I_1(t)} (1 - \mathbb{E}[p_2])^{I_2(t)} (1 - \mathbb{E}[p_3])^{I_3(t)} \dots \dots \dots$$

$$(1 - \mathbb{E}[\text{skull} p_1])^{I_{av1}(t)} (1 - \mathbb{E}[\text{skull} p_2])^{I_{av2}(t)} (1 - \mathbb{E}[\text{skull} p_3])^{I_{av3}(t)} \dots \dots \dots$$

- Infection probability

- ◆  $P(t) = 1 - Q(t)$


- Generate random number  $[0,1]$

- Repeat for every susceptible on day  $t$


# Bipartite Graph

People

Places



# Weighted Person-to-Person Graph



### Daily contact probabilities adults by mixing group


Contact group	Children					Adults
	Pre-School		School			
	Small Playgroup	Large Daycare	Elementary	Middle	High	
Small playgroups	0.35					
Large playgroups		0.25				
Elementary school			0.062			
Middle school				0.062		
High school					0.062	
Family						
Child	0.60	0.60	0.60	0.60	0.60	0.30
Adult	0.30	0.30	0.30	0.30	0.30	0.40
Neighborhood Cluster						
Child	0.15	0.15	0.15	0.15	0.15	0.08
Adult	0.08	0.08	0.08	0.08	0.08	0.10
Hospital Flu ward						
Worker-worker						0.01250
Patient-worker	0.01000	0.01000	0.01000	0.01000	0.01000	0.01000
Patient-visitor	0.01000	0.01000	0.01000	0.01000	0.01000	0.01000
Other wards						0.00250
Workgroup						0.08
Social Groups	0.0018	0.0018	0.0020	0.0020	0.0020	0.0040

### Average Daily Contact Degree, by Mixing Group


Contact group	Children					Adults
	Pre-School		School			
	Small Playgroup	Large Daycare	Elementary	Middle	High	
Small playgroups	0.98					
Large playgroups		5.2				
Elementary school			7.2			
Middle school				5.9		
High school					4.2	
Family						
Child	0.37	0.37	0.37	0.37	0.37	0.72
Adult	0.48	0.48	0.48	0.48	0.48	0.56
Neighborhood Cluster						
Child	0.56	0.56	0.56	0.56	0.56	0.75
Adult	0.38	0.38	0.38	0.38	0.38	0.84
Hospital						
Flu ward						
Worker-worker						1.9
Patient-worker	-	-	-	-	-	-
Patient-visitor	-	-	-	-	-	-
Other wards						1.4
Workgroup						
Social Groups	0.20	0.20	0.27	0.27	0.27	0.95

# Degree Distribution

Histogram of degree



Contact Graph




Information and Settings

Basic Information


Degree: 2	Clustering Coefficient: 1.0
id: 1565	age category: 6
subpop: 1	community: 1 area: 4
family: 440	neighborhood: 113
daycare: 0	school: 0
work group: 2261	hospital: 0
social group 1: 109	social group 2: 139

Control

Zoom   Show floating information



Contact Graph




Information and Settings

Basic Information


Degree: 5	Clustering Coefficient: 0.0
id: 1568	age category: 6
subpop: 1	community: 1 area: 4
family: 441	neighborhood: 114
daycare: 0	school: 0
work group: 119	hospital: 0
social group 1: 37	social group 2: 44

Control

Zoom   Show floating information



## Contact Graph



## Information and Settings

## Basic Information

Degree: 17    Clustering Coefficient: 0.13

id: 550 age category: 3

subpop: 1    community: 1    area: 2

family: 160    neighborhood: 41

daycare: 0    school: 1

work group: 0    hospital: 0


social group 1: 79    social group 2: 113

## Control

Zoom 100% ▾

 Show floating information

## Cluster View



# Average Contact Matrix

		From							
		< 6 m	6 m - 4	5 - 10	11- 14	15 -17	18-44	45-64	65+
age group	To								
< 6 m		1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0
6 m - 4		1.0	3.9	1.0	1.0	1.0	1.1	1.1	1.1
5 - 10		1.1	1.1	7.5	1.1	1.1	1.1	1.1	1.1
11 - 14		1.0	1.0	1.0	5.9	1.0	1.0	1.0	1.1
15 - 17		1.0	1.0	1.0	1.0	4.2	1.0	1.0	1.1
18 - 44		1.3	1.4	1.4	1.4	1.4	2.2	2.1	2.4
45 - 64		1.1	1.1	1.1	1.1	1.1	1.4	1.4	1.4
65+		1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2

## Estimated mean numbers of conversations per week, The Netherlands, 1986\*

Age class	1-4	5-12	13-19	20-39	40-59	60+
0-4	12.3	2.3	1.3	2.5	1.2	0.8
5-12	2.7	23.8	2.8	3.0	1.8	1.0
13-19	2.0	3.6	25.2	5.7	4.2	1.7
20-39	11.5	11.6	16.9	25.1	16.4	8.3
40-59	3.6	4.7	8.5	11.2	13.9	7.5
60+	1.9	2.0	2.5	4.3	5.6	9.2

\*Wallinga, et al., unpublished manuscript


# Next Generation Matrix $\mathbf{R}$

age group	From							
	0	1	2	3	4	5	6	7
0	0.10	0.10	0.10	0.10	0.10	0.10	0.10	0.10
1	0.11	0.40	0.11	0.11	0.11	0.11	0.11	0.11
2	0.11	0.11	0.77	0.11	0.11	0.11	0.11	0.11
To 3	0.11	0.11	0.11	0.61	0.11	0.11	0.11	0.11
4	0.11	0.11	0.11	0.11	0.43	0.11	0.11	0.11
5	0.14	0.14	0.14	0.14	0.14	0.22	0.22	0.25
6	0.12	0.12	0.12	0.12	0.12	0.14	0.14	0.15
7	0.11	0.11	0.11	0.11	0.11	0.12	0.12	0.12



Basic reproduction number  $R_0 = 1.2$

# Infection Transmission Process

# Modeled natural history of influenza



Serial interval: Mean 2.3 days




# Use of Oseltamivir

- Each person to be treated is given a single course of Oseltamivir
  - ◆ 5 days of treatment
- Each person to be prophylaxed is given a single course of Oseltamivir
  - ◆ 10 days of prophylaxis


# Some Results

$R_0^*$ : Number of people infected by a single initial infective



\* Based on 1000 simulations

# Probabilities and Epidemic Sizes: No Intervention






# Simulated pandemic influenza outbreak

$$R_0 = 1.4$$

Without  
intervention



80% TAP





# Simulated pandemic influenza outbreak

$$R_0 = 1.7$$

80% TAP




80% TAP  
+ 50% Pre-vacc




# Simulated pandemic influenza outbreak

$$R_0 = 1.7$$

70% reactive  
vaccination



No intervention





# Simulated pandemic influenza outbreak

$$R_0 = 1.7$$

70% reactive  
vaccination




70% reactive  
vaccination  
+ 80% TAP




# Simulated pandemic influenza outbreak

$$R_0 = 1.7$$


70% reactive  
vaccination




70% pre-prime  
post boost




# 70% reactive vaccination $R_0=1.2$ intervention at day 18





# 70% reactive vaccination $R_0=1.7$ intervention at day 18



# Comparison of epidemic size for 70% reactive vaccination and baseline at $R_0=1.7$







# Largest $R_0$ with 90% EPP for each scenario

---

Scenarios	$R_0$
50% pre-vaccination	1.6
70% pre-vaccination	2.1
70% ring vaccination	1.2
70% reactive vaccination	1.3
80% TAP	1.6
80% TAP + 70% pre-vaccination	2.1
80% TAP + 70% ring vaccination	1.8
70% pre-prime post-boost ring vaccination	2.1
70% pre-prime post-boost reactive vaccination	2.1

---

# Conclusions: Containment

- TAP alone is sufficient for  $R_0 \leq 1.6$
- Yearly pre-vaccination with pre-pandemic vaccine would be best, but obviously impossible
- Reactive mass vaccination is somewhat better than ring vaccination
- Reactive vaccination would only work for  $R_0 \leq 1.3$
- TAP + reactive vaccination would work for  $R_0 \leq 2.1$
- Pre-prime, post boost vaccination would work for  $R_0 \leq 2.0$
- Reactive and ring vaccination should be started no less than two weeks after the initial case

# Conclusions

- Mitigation targeting with limited quantities of vaccine
  - Vaccination school children
  - High Risk
  - Essential workforce
- Probably the pre-prime, post boost vaccination strategy is more sure and robust than any other strategy